Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Bostwick warns US-based biotechs today against trying to beat China on cost by simply running the same playbook. He says Breyer wants paradigm-shifting, hard-to-reproduce innovation with a learning flywheel; truly copycat strategies are unlikely to attract investment when Chinese execution is faster and cheaper.

Related Insights

Previously, being fourth or fifth to market could still lead to blockbuster success. Now, with Chinese biotechs excelling at creating "me-better" drugs, laggard companies risk becoming "brand generics" pre-launch, underscoring the need for genuine differentiation.

The high cost and time required for US clinical trials create a rational economic incentive for companies and investors to move operations to China. The solution isn't to match China's low costs, but to significantly improve US efficiency to make domestic investment more competitive.

When prioritizing pipelines, biotechs must consider commercial viability, not just science. With China's ecosystem specializing in fast-follow "Me Too" drugs, such assets are becoming commoditized. To secure funding and premium exits, companies must focus on truly differentiated "first-in-class" or "best-in-class" programs.

China is replicating its state-driven model for industries like automotive in bioprocessing. However, Chinese firms themselves recognize that simply copying Western methods is unprofitable. This creates a global race where both Western and Chinese companies must innovate on process technology, not just cost, to gain a competitive edge.

Western drug discovery companies face their primary competition not from fellow AI startups, but from highly efficient traditional Chinese biopharma companies. To remain competitive and learn local performance standards, companies must build physical infrastructure and establish significant operational footprints directly in China.

To compete with China's rapid 'me-better' development, U.S. innovators should proactively partner with Chinese firms to create improved versions of their own drugs. This self-cannibalization strategy is necessary to stay ahead before competitors do it for them.

Acknowledging that China's development speed for known targets is "unparalleled," the CEO's strategy is not to match it. Instead, the competitive edge comes from the innovative front-end: discovering novel target pairings from a proprietary platform that others cannot.

Faced with China's superior speed and cost in executing known science, the U.S. biotech industry cannot compete by simply iterating faster. Its strategic advantage lies in

John Crowley, CEO of Bio, argues the best strategy for US biotech dominance is not protectionism. Instead, the focus should be on improving the US's own competitive advantages, like streamlining regulations and lowering innovation costs, to maintain its lead rather than trying to stifle Chinese research.

The next decade in biotech will prioritize speed and cost, areas where Chinese companies excel. They rapidly and cheaply advance molecules to early clinical trials, attracting major pharma companies to acquire assets that they historically would have sourced from US biotechs. This is reshaping the global competitive landscape.